Harm Sinnige

3.6k total citations · 1 hit paper
29 papers, 2.2k citations indexed

About

Harm Sinnige is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Harm Sinnige has authored 29 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Hematology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Harm Sinnige's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and Multiple Myeloma Research and Treatments (8 papers). Harm Sinnige is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and Multiple Myeloma Research and Treatments (8 papers). Harm Sinnige collaborates with scholars based in Netherlands, Belgium and France. Harm Sinnige's co-authors include Cornelis J.A. Punt, Linda Mol, Miriam Koopman, Ninja Antonini, Frans Erdkamp, C. J. Rodenburg, Otilia Dalesio, D. J. Richel, Cees J. van Groeningen and Allert H. Vos and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Harm Sinnige

27 papers receiving 2.1k citations

Hit Papers

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Co... 2009 2026 2014 2020 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
    2009 1.0k citations Miriam Koopman, Harm Sinnige et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harm Sinnige Netherlands 11 1.6k 569 540 436 416 29 2.2k
Martin Šmakal United States 11 2.1k 1.3× 896 1.6× 398 0.7× 179 0.4× 385 0.9× 26 2.6k
M. Flesch France 23 1.8k 1.1× 620 1.1× 240 0.4× 669 1.5× 455 1.1× 72 2.6k
D. Voliotis Germany 20 953 0.6× 604 1.1× 970 1.8× 312 0.7× 1.4k 3.3× 48 3.0k
N. Schleucher Germany 19 802 0.5× 610 1.1× 598 1.1× 161 0.4× 172 0.4× 32 1.6k
Jean-Luc Canon Belgium 15 2.3k 1.4× 1.1k 1.9× 314 0.6× 139 0.3× 486 1.2× 31 2.8k
M Krulik France 20 1.4k 0.9× 571 1.0× 225 0.4× 300 0.7× 397 1.0× 115 2.0k
Allert H. Vos Netherlands 8 1.3k 0.8× 542 1.0× 263 0.5× 92 0.2× 314 0.8× 11 1.6k
Jane Robertson United Kingdom 22 1.3k 0.8× 510 0.9× 816 1.5× 121 0.3× 225 0.5× 57 2.0k
Christian Rothermundt Switzerland 25 1.0k 0.6× 971 1.7× 755 1.4× 285 0.7× 81 0.2× 79 2.3k
Daniel Hendler Israel 7 2.7k 1.7× 824 1.4× 335 0.6× 100 0.2× 899 2.2× 19 3.2k

Countries citing papers authored by Harm Sinnige

Since Specialization
Citations

This map shows the geographic impact of Harm Sinnige's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harm Sinnige with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harm Sinnige more than expected).

Fields of papers citing papers by Harm Sinnige

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harm Sinnige. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harm Sinnige. The network helps show where Harm Sinnige may publish in the future.

Co-authorship network of co-authors of Harm Sinnige

This figure shows the co-authorship network connecting the top 25 collaborators of Harm Sinnige. A scholar is included among the top collaborators of Harm Sinnige based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harm Sinnige. Harm Sinnige is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huls, Gerwin, Dana Chiţu, Violaine Havelange, et al.. (2019). Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 133(13). 1457–1464. 119 indexed citations
2.
Melenotte, Cléa, Mirjam H. A. Hermans, Harm Sinnige, et al.. (2017). Case report: Coxiella burnetii vascular infection and lymphoma in the Netherlands. Infection. 46(1). 131–134. 9 indexed citations
3.
Derikx, Lauranne, et al.. (2016). Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy. World Journal of Gastroenterology. 22(47). 10465–10465. 7 indexed citations
4.
5.
Lokhorst, Henk M., Bronno van der Holt, Sonja Zweegman, et al.. (2013). Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial. Blood. 122(21). 3332–3332. 1 indexed citations
6.
Venderbosch, Sabine, Johannes H.W. de Wilt, Steven Teerenstra, et al.. (2012). Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. Indian Journal of Surgical Oncology. 3(1). 57–65. 7 indexed citations
7.
Venderbosch, Sabine, Johannes H.W. de Wilt, Steven Teerenstra, et al.. (2011). Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. Annals of Surgical Oncology. 18(12). 3252–3260. 125 indexed citations
8.
Verelst, S., Fabian Termorshuizen, Carin A. Uyl‐de Groot, et al.. (2011). Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Annals of Hematology. 90(12). 1427–1439. 29 indexed citations
9.
10.
11.
Wijermans, Pierre W., M. Ronald Schaafsma, Fabian Termorshuizen, et al.. (2010). Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study. Journal of Clinical Oncology. 28(19). 3160–3166. 189 indexed citations
12.
13.
14.
Spek, Ellen van der, A C Bloem, Harm Sinnige, & H M Lokhorst. (2007). High dose Simvastatin does not reverse resistance to Vincristine, Adriamycin, and Dexamethasone (VAD) in Myeloma. Haematologica. 92(12). e130–e131. 24 indexed citations
15.
Koopman, Miriam, Ninja Antonini, Gerard Vreugdenhil, et al.. (2007). 3047 POSTER Resection of the primary tumour as an independent prognostic factor for survival in patients with advanced colorectal cancer. CAIRO study of the Dutch Colorectal Cancer Group (DCCG). European Journal of Cancer Supplements. 5(4). 250–250. 1 indexed citations
16.
Borst, F, et al.. (2004). High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Annals of Hematology. 83(12). 764–768. 49 indexed citations
17.
Pruyn, J.F.A., et al.. (2003). On the enhancement of efficiency in care for cancer patients in outpatient clinics: an instrument to accelerate psychosocial screening and referral. Patient Education and Counseling. 53(2). 135–140. 24 indexed citations
18.
Smilde, TJ, et al.. (2002). [Three patients with massive pulmonary embolism].. PubMed. 146(4). 184–6.
19.
Buter, Jan, Harm Sinnige, Dirk Th. Sleijfer, et al.. (1995). 5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer. 75(5). 1072–1076. 4 indexed citations
20.
Sinnige, Harm, Jan Buter, Elisabeth G.E. de Vries, et al.. (1993). Phase I–II study of the addition of α-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of α-2a interferon and leucovorin. European Journal of Cancer. 29(12). 1715–1720. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Šmakal Breakdown of academic impact, for papers by M. Flesch Breakdown of academic impact, for papers by D. Voliotis Breakdown of academic impact, for papers by N. Schleucher Breakdown of academic impact, for papers by Jean-Luc Canon Breakdown of academic impact, for papers by M Krulik Breakdown of academic impact, for papers by Allert H. Vos Breakdown of academic impact, for papers by Jane Robertson Breakdown of academic impact, for papers by Christian Rothermundt Breakdown of academic impact, for papers by Daniel Hendler
Rankless by CCL
2026